



# Retevmo in Qatar

*The MOPH named-patient coordination pathway — indicative 2026*

ONCOLOGY · RET-ALTERED CANCERS

## The clinical situation

Retevmo (selpercatinib) is a selective oral RET kinase inhibitor with activity in RET-fusion cancers (NSCLC, thyroid) and RET-mutant medullary thyroid cancer. Manufactured by Eli Lilly. Eligibility requires molecular confirmation of the RET alteration; dosing is typically 160 mg twice daily (weight-based at lower weights), with monitoring for hypertension, QTc, liver enzymes, haemorrhage, and allergic reactions.

### The pathway, 5 steps

- 1 Consultation & clinical rationale.** Your treating oncologist confirms RET status and documents a written clinical rationale.
- 2 Administering facility confirmed.** A Qatari tertiary oncology centre with an importing pharmacy is identified.
- 3 MOPH named-patient application.** Clinical rationale, patient reference, product details, and chain-of-custody plan are filed.
- 4 US-side sourcing & logistics.** Reserve Meds coordinates product through our US-licensed DSCSA-compliant specialty wholesale partner.
- 5 Arrival & administration.** The pharmacy releases product against prescription; concierge coordinates monthly re-supply ahead of cycle end.

### Indicative economics

**Reference US cash-pay range:** USD 21,000–24,000 per 30-day supply. Logistics, MOPH documentation, and concierge coordination are incremental. Full transparent quote at intake.

### Indicative first-dose timing

**7–14 days** from a complete MOPH application to first delivery, once cohort intake opens. Indicative — not guaranteed.

## Reserve Meds's role

**Sourcing.** US-licensed specialty wholesale partner, DSCSA chain-of-custody. **Documentation.** Regulatory package for your physician and MOPH review. **Logistics.** Temperature- and chain-of-custody-compliant shipment. **Concierge case lead.** Named point of contact for family and physician through the full process. **We are a coordinator** — not the prescriber, not the dispensing pharmacy. All clinical decisions remain with your treating oncologist.

**COMPOSITE EXAMPLE · PRE-LAUNCH WAITLIST**

**Join the Retevmo × Qatar first-cohort waitlist.** *Our concierge reaches out as we open intake.*

[reservemed.com/access-guides/retevmo-qatar.html](https://reservemed.com/access-guides/retevmo-qatar.html)



SCAN TO JOIN

**Reserve Meds** · US-based concierge for cross-border specialty medicine. We are a coordinator; we are not the prescriber and not the dispensing pharmacy. All clinical decisions remain with the treating physician. Not medical advice.

*Reserve Meds is in pre-launch. Service availability is limited to our first cohort; all timelines published are indicative, not guarantees. Composite case examples only.*

**reservemed.com** · [hello@reservemed.com](mailto:hello@reservemed.com) · WhatsApp concierge: +1 516 528 3120 · Reviewed 2026-04-23 by Reserve Meds clinical & regulatory team